ProShare Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

ProShare Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$174K	Sell	11,622 -1,403	-11%	-$19.5K	﹤0.01%	1679
2026 Q1	$191K	Sell	13,025 -739	-5%	-$11.8K	﹤0.01%	1604
2025 Q4	$106K	Buy	13,764 +979	+8%	+$7.72K	﹤0.01%	1863
2025 Q3	$94.2K	Sell	12,785 -835	-6%	-$4.27K	﹤0.01%	1854
2025 Q2	$54.5K	Buy	+13,620	New	+$49.6K	﹤0.01%	1980
2018 Q4	–	Sell	-13,604	Closed	-$117K	–	1604
2018 Q3	$117K	Sell	13,604 -491	-3%	-$4.91K	﹤0.01%	1667
2018 Q2	$155K	Buy	14,095 +3,291	+30%	+$36.7K	﹤0.01%	1664
2018 Q1	$125K	Sell	10,804 -1,783	-14%	-$16.9K	﹤0.01%	1619
2017 Q4	$130K	Buy	+12,587	New	+$161K	﹤0.01%	1711

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ProShare Advisors's CRVS Position: Q2 2026 in Review

ProShare Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 11% in Q2 2026, selling an estimated $19.5K and leaving 11,622 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

ProShare Advisors first reported a position in CRVS in Q4 2017 and has held it in 9 quarters since. The position peaked at $191K in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

ProShare Advisors held 11,622 shares of Corvus Pharmaceuticals worth $174K as of Q2 2026.
ProShare Advisors sold 1,403 Corvus Pharmaceuticals shares in Q2 2026, an estimated $19.5K.
Corvus Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1679 holding.
ProShare Advisors first reported a position in Corvus Pharmaceuticals in Q4 2017 and has held it in 9 quarters since.
ProShare Advisors's Corvus Pharmaceuticals position peaked at $191K in Q1 2026.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.